Huntington's disease does not appear to increase the risk of diabetes mellitus

Journal of Neuroendocrinology

Volumn 21, Issue 9, 2009, Pages 770-776

  Boesgaard, T W ^a   Nielsen, T T ^b   Josefsen, K ^c   Hansen, T ^a,d   Jorgensen T ^e,f   Pedersen, O ^a,f,g   Norremolle A ^b   Nielsen, J E ^b,c   Hasholt, Lis ^b  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

Author keywords

Diabetes; Huntington's disease; Lentiviral vector

Indexed keywords

GLUCOSE; HUNTINGTIN; INSULIN; NEUROPEPTIDE; POLYGLUTAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HUNTINGTON CHOREA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION;

ADULT; AGED; ANIMALS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CELLS, CULTURED; DIABETES MELLITUS; FEMALE; HUMANS; HUNTINGTON DISEASE; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MIDDLE AGED; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RISK FACTORS; TRANSDUCTION, GENETIC;

EID: 69249108498     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2009.01898.x     Document Type: Article

References (46)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, Gusella J, MacDonald ME. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994; 20: 27-38.
3. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin de BL, Bonilla E. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 1989; 50: 145-150.
4. Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L. Use of oral nutritional supplements in patients with Huntington's disease. Nutrition 2005; 21: 889-894.
5. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet 2004; 20: 146-154.
6. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995; 14: 1065-1074.
7. Greenamyre JT. Huntington's disease: Getting closer. Am J Psychiatry 2007; 164: 1318.
8. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, Clark TW, Bouzou B, Cha JH. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008; 28: 10720-10733.
9. Podolsky S, Leopold NA, Sax DS. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; 1: 1356-1358.
10. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet 1985; 27: 62-67.
11. Davidson MB, Green S, Menkes JH. Normal glucose, insulin, and growth hormone responses to oral glucose in Huntington's disease. J Lab Clin Med 1974; 84: 807-812.
12. Phillipson OT, Bird ED. Plasma glucose, non-esterified fatty acids and amino acids in Huntington's chorea. Clin Sci Mol Med 1977; 52: 311-318.
13. Kremer HP, Roos RA, Frolich M, Radder JK, Nieuwenhuijzen Kruseman AC, Van d V, Buruma OJ. Endocrine functions in Huntington's disease. Atwo-and-a-half years follow-up study. J Neurol Sci 1989; 90: 335-344.
14. Schubotz R, Hausmann L, Kaffarnik H, Zehner J, Oepen H. [Fatty acid patterns and glucose tolerance in Huntington's chorea (author's translation)]. Res Exp Med (Berl) 1976; 167: 203-215.
15. Lalic NM, Maric J, Svetel M, Jotic A, Stefanova E, Lalic K, Dragasevic N, Milicic T, Lukic L, Kostic VS. Glucose homeostasis in Huntington disease: Abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 2008; 65: 476-480.
16. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK. Huntington's disease of the endocrine pancreas: Insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 2002; 11: 410-424.
17. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, Freed CR. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999; 48: 649-651.
18. Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 2005; 14: 565-574.
19. Hunt MJ, Morton AJ. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 2005; 166: 220-229.
20. Van DA, Blakemore C, Deacon R, York D, Hannan AJ. Delaying the onset of Huntington's in mice. Nature 2000; 404: 721-722.
21. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 1999; 96: 8727-8732.
22. Josefsen K, Nielsen MD, Jorgensen KH, Bock T, Norremolle A, Sorensen SA, Naver B, Hasholt L. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J Neuroendocrinol 2008; 20: 165-172.
23. Duan W, Guo Z, Jiang H, Ware M, Mattson MP. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003; 144: 2446-2453.
24. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
25. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 2003; 100: 2911-2916.
26. Shoulson I. Huntington disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981; 31: 1333-1335.
27. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: Baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003; 10: 377-386.
28. World Health Organisation Study Group. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999.
29. Hasholt L, Abell K, Norremolle A, Nellemann C, Fenger K, Sorensen SA. Antisense downregulation of mutant huntingtin in a cell model. J Gene Med 2003; 5: 528-538.
30. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
32. Nellemann C, Abell K, Norremolle A, Lokkegaard T, Naver B, Ropke C, Rygaard J, Sorensen SA, Hasholt L. Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Mol Cell Neurosci 2000; 16: 313-323.
33. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
34. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
35. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
36. Jakobsson J, Rosenqvist N, Thompson L, Barraud P, Lundberg C. Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4 insulator. Exp Cell Res 2004; 298: 611-623.
37. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 2004; 145: 667-678.
38. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 1992; 130: 167-178.
39. O'Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421-5426.
40. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: Behavioral testing and impact of diabetes mellitus. Behav Brain Res 2001; 126: 185-195.
41. Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 2003; 7: 572-579.
42. Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 2001; 50: 112-117.
43. Bacos K, Bjorkqvist M, Petersen A, Luts L, Maat-Schieman ML, Roos RA, Sundler F, Brundin P, Mulder H, Wierup N. Islet beta-cell area and hormone expression are unaltered in Huntington's disease. Histochem Cell Biol 2008; 129: 623-629.
44. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813-822.
45. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-142.
46. Nørremølle A, Budtz-Jørgensen E, Fenger K, Nielsen JE, Sørensen SA, Hasholt L. 4p16.3 haplotype modifying age at onset of Huntington disease. Clin Genet 2009; 75: 244-50.